Cotargeting DNA topoisomerase II enhances efficacy of RAS-targeted therapy in KRAS-mutant cancer models.

Although the difference did not reach statistical significance due to the small sample size, low Topo IIα expression trended toward longer mPFS (not reached vs. 5.3 months, P = 0.291; Figure 10E ) and higher ORR (40.0% [2/5] vs. 25.0% [1/4], P > 0.999; Figure 10F ).

also in 111,027 other papers